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Background: Little is known about the role of guidelines for the practical management of 
chronic obstructive pulmonary disease (COPD) by office-based pulmonary specialists. The 
aim of this study was to assess their outpatient management in relation to current guideline 
recommendations for COPD.
Methods: A nationwide prospective cross-sectional COPD questionnaire survey in the form 
of a multiple-choice questionnaire was sent to 1000 office-based respiratory specialists in 
  Germany. The product-neutral questions focused on routine COPD management and were 
based on   current national and international COPD guideline recommendations being consistent 
in severity classification and treatment recommendations.
Results: A total of 590 pulmonary specialists (59%) participated in the survey. Body plethys-
mography was considered the standard for diagnosis (65.9%), followed by spirometry (32%). 
Most respondents were able to cite the correct spirometric criteria for classifying moderate 
(87%) to very severe COPD (77%). A quarter of the respondents equated the World Health 
Organization (WHO) definition of chronic bronchitis with COPD. Notably, most participants 
preferred the updated national COPD guidelines (51.4%) to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines (40.2%). Improvement of functional exercise 
capacity and quality of life were considered the two most relevant treatment goals; whereas 
impact on mortality was secondary. Treatment of COPD largely complied with the guidelines. 
However, a significant percentage of the pulmonary specialists differed in their assessment of 
the benefits of various therapeutic measures from evidence-based results. Referral for pulmonary 
rehabilitation was uncommon, regardless of the severity of COPD.
Conclusion: The findings of this large national survey suggest that most pulmonary specialists 
adhere to the current COPD guideline recommendations in daily practice. However, physicians’ 
knowledge of guidelines is not sufficient as the sole benchmark when assessing their implemen-
tation in day-to-day practice. Necessary changes in the health care system must include more 
effective ways to transfer knowledge to clinical practice and to give access to interventions of 
proven clinical benefit.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the most significant 
chronic conditions worldwide and is now the fourth most common cause of death, 
resulting in an enormous, steadily increasing economic and social burden.1–3 COPD 
is regarded as a preventable and treatable disease. Consequently, greater focus on 
early diagnosis and appropriate treatment may prevent and improve symptoms, 
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reduce the rate and severity of exacerbations, improve 
quality of life, improve exercise capacity and physical 
activity, and prolong survival.4 In recent years, evidence-
based clinical guidelines have been developed at both 
the national and international level in an effort to help 
doctors diagnose, treat, and prevent this condition.5–7 The 
diagnostic and therapeutic recommendations of the current 
German COPD guidelines are based on the international 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines.7
A number of studies suggest that there are substantial 
gaps between recommended and real life management of 
COPD patients in primary care practice.8–13 The extent to 
which guidelines are accepted and implemented differs 
widely from one group of doctors to another.14 We hypoth-
esized that pulmonary specialists, who generally have a 
better knowledge of lung diseases, are more likely to adhere 
to COPD guidelines.15 In general, little is known about the 
current practice patterns of respiratory specialists in outpa-
tient care. A recent survey studied the guideline conformity 
of COPD management among pulmonary specialists and 
general practitioners, revealing deficiencies with regard to 
the diagnosis, treatment, and implementation of educational 
measures in COPD.16 However, this study was based on 
the outdated German COPD guidelines from 200217 which 
differed from the current German and GOLD guidelines 
in essential points, such as the classification of COPD 
severity and treatment. The aim of this nationwide survey 
with 1000 office-based pulmonary specialists in Germany 
was to investigate their COPD management and how this 
compares with current national and international guideline 
recommendations.
Methods
Anonymized questionnaires were sent with a stamped 
addressed envelope to 1000 office-based pulmonary 
specialists (or pulmonary group practices) in Germany. 
Physicians were selected from a representative national 
physicians’ register. There was a total of 1088 office-
based pulmonary specialists at the time of the investiga-
tion (OneKey database, Cegedim, Bensheim, Germany). 
Academic institutions or hospitals were not included in 
the survey.
The self-administered postal questionnaire survey was 
based on current national COPD guidelines.5,7 It had 43 mul-
tiple choice questions, focusing on the following items:
•	 Epidemiology and diagnosis of COPD
•	 Patient education
•	 Treatment
•	 Knowledge  and  acceptance  of  current  COPD 
guidelines
•	 Questions regarding the physici  an’s practice.
The questionnaire had been applied in a similar format 
in a previous survey.16 Non-responders were not followed up 
and no reminders were sent during the 4-month term of the 
survey. Physicians were paid 75 euro as compensation for 
participation in the survey.
Statistics
DCAS (DCAS Software Solutions Inc, Plano, TX) software 
(Medidata GmbH, Konstanz, Germany) and SAS software 
(v 9.1.3; SAS Institute Inc, Cary, NC) were used for statistical 
analysis of the anonymous, machine-readable   questionnaires. 
The frequencies for each category, in relation to the total 
  number of responses, are given in text results and Tables 1–3. 
The   anonymized data were analyzed by Medidata.
Results
Demographics
Fifty-nine percent of the 1000 questionnaires sent out were 
returned (n = 590 physicians). Ninety-six percent of the 
physicians were pulmonary specialists. The data quality 
was very good, as reflected by the low frequency of missing 
data (#3.1%). The demographic data of the participants 
are shown in Table 1. Forty-eight percent of pulmonary 
specialists reported that they treat 101–200 COPD patients 
per month. Thirty-six percent of the physicians reported 
treating .200 COPD patients per month, primarily patients 
with moderate COPD. Fifty-four percent of the respondents 
reported that 5%–15% of their patients showed an overlap 
of asthma and COPD.
Epidemiology and risk factors
The incidence of COPD is increasing according to 90% of 
the physicians and 94% of the physicians regard COPD as 
a big or very big “public health” problem in Germany. The 
two most important risk factors for COPD were smoking 
(99% of the physicians) and air pollution (37%), followed 
by bacterial and/or viral infections (29%) and genetic pre-
disposition (26%). Almost half of the respondents (49%) 
reported that 16%–30% of their patients experienced an 
exacerbation per year requiring therapy with systemic ste-
roids and/or antibiotics. Eighteen percent of the physicians 
stated that 31%–50% of their COPD patients had at least 
one moderate exacerbation per year. Hospitalizations due 
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severity of severe (GOLD III) and very severe (GOLD IV) 
COPD, respectively.
Patient education
Ninety-seven percent of the physicians stated that they or their 
staff regularly instructed patients in the correct use of inhalers. 
Most   physicians advised their patients to stop smoking at every 
visit: (moderate COPD 78%, severe/very severe COPD 83%) or 
several times a year (moderate COPD 20% severe/very severe 
COPD 14%). A total of 60% of the respondents considered it dif-
ficult to implement measures to help patients give up smoking.
Table 1 Demographic characteristics of respondents (n = 590)
Proportion (n and %)
Age group 
  30–40 years 
  41–50 years 
  51–60 years 
  .60 years 
  Missing data
 
46 (7.8) 
240 (40.7) 
225 (38.1) 
70 (11.9) 
9 (1.5)
Sex 
  Men 
  Women 
  Missing data
 
447 (75.8) 
132 (22.4) 
11 (1.9)
Specialty 
  Pulmonologist 
  Internist 
  Missing data
 
565 (95.8) 
15 (2.5) 
10 (1.7)
Location of practice 
  Urban 
  Rural 
  Missing data
 
285 (48.3) 
289 (49.0) 
17 (2.9)
Practice type 
  Single practice 
  Single-speciality group practice 
  Multi-speciality group practice 
  Missing data
 
269 (45.6) 
214 (36.3) 
95 (16.1) 
13 (2.2)
Length of time in practice 
  ,5 years 
  5–10 years 
  11–20 years 
  .20 years 
  Missing data
 
152 (25.8) 
123 (20.8) 
209 (35.4) 
96 (16.3) 
10 (1.7)
to exacerbations were reported less frequently: 61% of the 
physicians stated that ,5% of their patients had at least one 
exacerbation-related hospitalization per year.
Diagnosis of COPD
Table 2 illustrates the respondents’ criteria for diagnosis 
of COPD. Ninety-one percent of the physicians stated that 
a diagnosis of “suspected COPD” is reasonable in patients 
showing symptoms such as cough, expectoration, shortness 
of breath, and/or risk factors for COPD. The most relevant 
test for patients with suspected COPD was considered to 
be body plethysmography (66% of pulmonary specialists), 
followed by spirometry (32%).
As reported by the physicians, diagnosis of COPD is 
primarily based on a forced expiratory volume in 1 second/
(forced) vital capacity (FEV1/VC) index of ,70% (61% of 
the physicians). On the other hand, 27% of the physicians 
used the WHO criteria for chronic bronchitis instead. Of the 
respondents, 85% applied the correct spirometric criteria 
to assess the severity of moderate (GOLD II) COPD, with 
87% and 77% of respondents using the criteria to assess the 
Table 2 Criteria used by respondents to diagnose COPD
Proportion (n and %)
Diagnostic criteria for COPD 
FEV1/VC ratio of ,70% predicted 
Cough and sputum for  
3 months in 2 consecutive years 
FEV1 of ,80% predicted 
FEV1 of ,1.5 L 
Signs of pulmonary emphysema  
on chest X-ray 
Hypoxemia and/or hypercapnia 
Missing data
 
358 (60.7) 
157 (26.6) 
 
53 (9.0) 
7 (1.2) 
5 (0.8) 
 
4 (0.7) 
12 (2.0)
Definition of moderate COPD 
FEV1/VC ratio of ,70% + FEV1  
of ,80% but $50% predicted 
FEV1/VC ratio of ,70% + FEV1  
of ,50% predicted 
Clinical symptoms (dyspnoea,  
reduced physical capacity) 
FEV1/VC ratio of ,50% 
FEV1 of .1 L 
Missing data
 
504 (85.4) 
 
63 (10.7) 
 
9 (1.5) 
 
5 (0.8) 
1 (0.2) 
10 (1.7)
Definition of severe COPD 
FEV1/VC ratio of ,70% + FEV1  
of ,50% but $30% predicted 
FEV1/VC ratio of ,50% 
Clinical symptoms  
(severe dyspnea at rest) 
FEV1 of ,1 L 
FEV1/VC ratio of ,70% + FEV1  
of ,80% predicted 
Missing data
 
514 (87.1) 
 
51 (8.6) 
15 (2.5) 
 
5 (0.8) 
2 (0.3) 
 
10 (1.7)
Definition of very severe COPD 
FEV1/VC ratio of ,70% + FEV1  
of ,30% predicted 
FEV1/VC ratio of ,70% + FEV1  
of ,50% predicted + chronic respiratory  
failure (signs of right-sided heart failure)1 
FEV1/VC ratio of ,30% 
Clinical symptoms (severe dyspnea  
at rest, frequent exacerbations) 
FEV1 of ,1 L 
Missing data
 
452 (76.6) 
 
327 (55.4) 
 
 
70 (11.9) 
30 (5.1) 
 
20 (3.4) 
11 (1.9)
Note: Respondents (n = 590) could give more than one answer to all questions.
Abbreviations: FEV1, forced expiratory volume in 1 second; VC, vital capacity.
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Treatment
The two most important indicators of successful treatment 
as stated by pulmonary specialists were improved func-
tional exercise capacity (72%) and quality of life (52%), 
followed by the prevention of exacerbations (Figure 1). The 
treatments prescribed by doctors for at least 50% of their 
patients with moderate to severe COPD based on the GOLD 
classification are summarized in Figure 2.   Long-acting 
bronchodilators (β2-agonists and/or anticholinergics) were 
the most commonly prescribed treatments.   Short-acting 
bronchodilators (β2-agonists or anticholinergics) and 
inhaled steroids, on the other hand, were rarely prescribed 
on their own. A combination of long-acting β2-agonists 
and long-acting anticholinergics is primarily prescribed 
for severe COPD. The percentage of patients with mod-
erate COPD treated with theophylline was low, but was 
markedly higher in severe COPD. Long-term treatment 
(.3 months) with inhaled steroids in combination with 
long-acting bronchodilators was used primarily for patients 
with severe to very severe COPD. A relatively low portion 
of patients with moderate and severe to very severe COPD 
were given a yearly influenza vaccination by pulmonary 
specialists (Figure 1).
The most important criteria for long-term therapy with 
inhaled glucocorticosteroids in addition to long-acting bron-
chodilators were COPD with FEV1 of ,50% and at least 
one exacerbation in the past year requiring treatment with 
systemic steroids and/or antibiotics (73% of the physicians) 
as well as improved symptoms due to inhaled glucocorti-
costeroids (71%). Of the pulmonary specialists, 85% said 
they prescribed oral glucocorticosteroids for a short time 
only in the case of exacerbations. Of the physicians, 62% 
felt pulmonary rehabilitation was indicated in the case of 
  moderate COPD (GOLD II), while 31% believed this was 
only necessary in severe forms of COPD (GOLD III 29%, 
GOLD IV 2%). In practice, only a small percentage of 
patients with moderate (2%) or severe/very severe COPD 
(16%) actually received pulmonary rehabilitation.
Assessment of the benefits of therapeutic 
measures
The results of an assessment of the benefits of various treat-
ments are given in Table 3. Nicotine abstinence was seen as 
the most effective measure for prolonging life expectancy 
and slowing down the progression of the disease. The 
major advantages of pulmonary rehabilitation were seen 
in an improvement in exercise capacity, quality of life, and 
symptoms.
The assessment of the benefits of short-acting bron-
chodilators (β2-agonists, anticholinergics) was based 
primarily on the improvement in clinical symptoms, 
exercise capacity, and quality of life. Compared with 
the benefits attributed to long-acting bronchodilators 
(β2-agonists, anticholinergics) – including the positive 
impact on   symptoms, exercise capacity, quality of life, 
and exacerbations –   theophylline was felt to be of lim-
ited clinical   benefit. Reductions in exacerbations were 
quoted in connection with long-acting bronchodilators, 
inhaled   corticosteroids, and the combination of these drugs. 
  Long-term oxygen therapy, when used, was seen as an 
effective measure for improving quality of life, exercise 
capacity, symptoms, and mortality. Contrary to the   evidence 
from clinical trials and guideline recommendations, long-
acting bronchodilators, inhaled corticosteroids, and pul-
monary rehabilitation were found to have some impact on 
disease progression and mortality.
01 02 03 0
Mortality
Cough/Mucus
Lung function
Exacerbations
Quality of life
Functional capacity
40 50 60 70 80
Proportion of sample (%)
Figure 1 The most relevant treatment goals for COPD as seen by pulmonary specialists.
Notes: Improvements in functional (exercise) capacity (72%) and quality of life (52%) were rated highest by the physicians, followed by a reduction of COPD exacerbations (44%). 
Effects on lung function (17%), cough/sputum production (12%) and, in particular, on mortality (3%) were seen as less important indicators of success. Two answers were 
required for this question; n = 590.
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Knowledge and acceptance of current 
COPD guidelines
Fifty-three percent of the participants regarded the recom-
mendations contained in the national and international 
guidelines for the diagnosis and treatment of COPD as very 
useful while 46% found them suitable for guidance. The 
most relevant guideline on diagnosis and therapy of COPD 
was the current national COPD guidelines (51%) followed 
by the international GOLD guidelines (40%).
Discussion
Evidence-based guidelines aim to improve the medical care 
of patients and support physicians in making the appropriate 
diagnosis and initiating adequate measures for prevention 
and therapy. This local survey investigated the outpatient 
management of practicing pulmonary specialists in relation 
to current guideline recommendations for COPD.
The updated German COPD Guidelines7 now conform 
to the international GOLD guidelines5,6 regarding severity 
classification and treatment recommendations. In the present 
survey, this realignment has led to improvements in COPD 
severity classification and treatment compared with a previ-
ous survey based on the former national COPD Guidelines 
of 2002.17 However, it must be pointed out that the national 
COPD guidelines, like the American Thoracic Society/ 
European Respiratory Society (ATS/ERS) consensus on 
clinical pulmonary function testing, defines obstruction on 
the basis of the FEV1/VC ratio.7,18 In borderline cases, this 
could mean discrepancies compared with GOLD.   Acceptance 
was high among the physicians questioned and in contrast 
Table 3 Evaluation of the clinical benefits of various treatments
Proportion of respondents (%)
Slows disease  
progression
Prolongs 
life
Improves physical  
capacity
Reduces  
exacerbation rate
Improves  
symptoms
Improves  
quality of life
No  
benefits
no smoking 94.9 86.1 79.5 76.3 75.1 74.2 0
SABD 2.4 3.7 68.8 9.2 91.7 48.5 1.4
LAMA 45.6 27.8 91.0 79.7 87.6 88.8 0.2
LABA 26.4 15.3 89.7 49.3 91.4 83.9 0.5
ICS 21.5 9.7 27.5 88.6 61.2 49.5 3.1
ICS + LABA 33.2 16.3 80.8 87.5 86.6 81.0 1.7
OCS 6.3 6.9 39.2 24.9 77.5 40.8 10.8
PR 28.6 32.4 92.5 45.8 75.6 89.5 1.7
LTOT 4.2 77.1 78.8 8.5 71.2 84.9 0.2
Theophylline 4.1 1.7 41.2 11.9 75.6 30.3 17.8
Note: Respondents (n = 590) could give more than one answer for any of the interventions.
Abbreviations: ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic agonists; LTOT, long-term oxygen therapy given for 16–24 
hours/day; OCS, oral corticosteroid; PR, pulmonary rehabilitation; SABD, short-acting bronchodilators.
01 02 04 0
OCS
Theophylline
SABD
Flu vaccination
ICS + LABD
LAMA
LAMA + LABA
LABA
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Proportion of sample (%)
Figure 2 Treatment given by pulmonary specialists to $50% of their patients.
Notes: Moderate COPD (white columns) or severe to very severe COPD (black columns) according to the GOLD severity classification.5 Several answers were possible 
for this question; n = 590.
Abbreviations: LAMA, long-acting muscarinic agonist; LABA, long-acting beta-agonists; ICS, inhaled corticosteroids; LABD, long-acting bronchodilators (LABA and/or 
LAMA); SABD, short-acting bronchodilators (SABA and/or SAMA); OCS, oral corticosteroids.
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to a previous survey there was a preference for the national 
COPD guidelines.16 This may be a reflection of the fact that 
the GOLD guidelines are aimed at an international readership 
with a wide range of access to health care and treatment, while 
the recommendations of the national COPD guidelines are 
tailored to the specifics of the German health care system.
Pulmonary specialists were well aware of the epidemiologi-
cal and health–economic dimensions of the disease. Questions 
about diagnosis criteria for COPD prompted different responses. 
More than half of the pulmonary specialists used the fixed FEV1/
VC ratio as a criterion for diagnosing COPD. On the other 
hand, 26.6% of the participants considered the classical WHO 
criterion of chronic bronchitis (former GOLD class 0) as an 
indicator for diagnosis. However, this was an 11.6% decrease 
compared with a previous study in the same country.16
There were slight deficiencies in terms of grading COPD 
according to spirometric criteria. About 85%–87% of par-
ticipants applied appropriate lung function criteria for the 
classification of moderate to severe COPD. There was greater 
disparity when describing very severe COPD – defined as 
either FEV1 , 30% or FEV1 , 50% predicted plus the pres-
ence of chronic respiratory failure – and this may indicate a 
particular degree of uncertainty with regard to the additional 
criteria of ventilatory failure or right heart insufficiency. 
Pulmonary specialists felt the most important aims of therapy 
were improvement in functional exercise capacity and quality 
of life, followed by prevention of exacerbations. This is well in 
line with the leading symptoms of patients with COPD, who 
primarily complain of shortness of breath upon exercise and 
the lasting impact of exacerbations. However, this survey did 
not explore how physicians’ views might differ from patients’ 
views. Interestingly, the positive impact on mortality was not 
of particular significance to physicians in terms of treatment 
objectives. This probably reflects the minor effect of symp-
tomatic medical treatment and the – at best – modest effect 
of interventions, such as oxygen therapy, on mortality. Given 
the practical relevance of physical activity to address disease 
progression and the impact of pharmacotherapy in COPD, the 
development of valid and practicable instruments to measure 
physical activity is urgently required.19–21
Two-thirds of the respondents prescribed a combination of 
a long-acting β2-agonist and an anticholinergic for more than 
half of their patients with severe COPD. Inhaled steroids and 
theophylline were also prescribed considerably more often 
in this patient group than for patients with moderate COPD. 
In line with the recommendations of current national and 
international guidelines, most pulmonary specialists prescribed 
systemic steroids for exacerbations only.5–7 The relatively low 
number of influenza vaccinations prescribed by pulmonary 
specialists contrasts with guideline recommendations. This 
might be explained by the fact that flu vaccinations are mainly 
performed by general practitioners in Germany.
Guidelines consider pulmonary rehabilitation to be stan-
dard care for those with at least moderate COPD (GOLD II) 
or at any stage in the presence of symptoms and disability.5–7 
However, pulmonary rehabilitation was not prescribed as often 
as it should have been despite the known benefits, even in the 
advanced stages of the disease. There is now strong support 
for pulmonary rehabilitation in the event of COPD following 
recent hospitalization for an exacerbation.22–25 Pulmonary reha-
bilitation could thus already be organized during hospitalization 
for an exacerbation. However, there are issues surrounding 
specific aspects of pulmonary rehabilitation in the local health 
system – for instance, the motivation of physicians and patients, 
a significant administrative burden, financial incentives, or the 
limited availability of qualified and certified centers – that are 
likely to have prevented more widespread implementation of 
pulmonary rehabilitation in Germany so far.
In some cases, assessment of the clinical benefit of vari-
ous pharmacological and non-pharmacological procedures, 
as offered by the office-based clinicians surveyed, conflicted 
with the clinical evidence from randomized clinical trials. For 
instance, so far no data are available from studies that corrobo-
rate the effect of pulmonary rehabilitation, bronchodilators, 
or inhaled steroids on mortality and the progression of the 
disease.5,6 We also found certain discrepancies between COPD 
guidelines and routine treatments. Some treatments such as 
inhaled corticosteroids (ICS) were overused in moderate 
COPD, whereas rehabilitation was not prescribed in a substan-
tial number of cases in which it would have been indicated. 
Finally, a significant percentage of respondents still used the 
WHO definition of chronic bronchitis to define COPD.
As is the case with all self-reported surveys, the results 
of this study can be neither generalized nor confirmed. It is 
also unclear to what extent there was any positive selection 
bias, recall bias, or if respondents’ answers differ from actual 
practice and knowledge or from those of non-pulmonary 
experts and non-participants. In addition, it remains unclear 
to what extent the treatment prescribed by physicians with 
a sound knowledge of the guidelines differs from that 
  suggested by physicians who are less familiar with the   current 
recommendations.
Overall, we found considerably greater conformity with 
guideline recommendations in terms of outpatient COPD 
management by pulmonary specialists compared to a   previous 
survey in 2005.16 This suggests a high level of knowledge 
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and significant progress in the implementation of COPD 
  guidelines in Germany. However, even among   pulmonary 
specialists there were certain deficits as regards the diagnosis 
and the pharmacological and non-pharmacological treatment 
of COPD. These gaps can be closed by using COPD guide-
lines for tailored education and training or as the founda-
tion of national disease management programs for COPD. 
  However, physicians’ knowledge of the guidelines is not suf-
ficient as the sole benchmark when assessing implementation 
of the guidelines in day-to-day   practice. Necessary changes 
in the health care system must include more effective ways 
to transfer knowledge to clinical practice and to give access 
to interventions of proven clinical benefit.
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